Leerink analyst David Larsen raised his price target for CVS Health (CVS) to $95 from $85 following quarterly results. The analyst is encouraged that the deal with Aetna (AET) appears to be ready to close in the near-term, which he believes will be a positive catalyst for the stock. Larsen also likes how the PBM selling season seems to be progressing well, better than he had expected, and also likes how CVS seems to be re-focusing on the Retail "Streamline" efforts, which will hopefully result in net savings in 2019. The analyst reiterates an Outperform rating on CVS shares.